Elsevier

Metabolism

Volume 58, Issue 3, March 2009, Pages 355-360
Metabolism

High-molecular-weight adiponectin is a predictor of progression to metabolic syndrome: a population-based 6-year follow-up study in Japanese men

https://doi.org/10.1016/j.metabol.2008.10.008Get rights and content

Abstract

Adiponectin is an adipocyte-specific secretory protein, which possesses antidiabetic and antiatherosclerotic properties. Adiponectin exists as multimers in serum, and high-molecular-weight (HMW) adiponectin is particularly considered to be the active form of the protein. The objective of the present study was to examine whether decreased HMW adiponectin is a predictor of progression to metabolic syndrome during a 6-year follow-up period in Japanese men. The study subjects were 416 Japanese men without metabolic syndrome, aged 30 to 59 years at baseline, who had participated in annual health checkups in both 2000 and 2006. Low concentration of HMW adiponectin (≤2.65 μg/mL) was associated with substantially higher hazard ratio of the progression to metabolic syndrome after adjustment for age and body mass index (hazard ratio, 1.561; 95% confidence interval, 1.051-2.292; P = .028). The number of subjects with the progression to metabolic syndrome in each tertile based on baseline HMW adiponectin concentration was significantly different among the 3 groups (HMW adiponectin: χ2 = 7.473, P = .0238; total adiponectin: χ2 = 4.477, P = .1066; HMW-total adiponectin ratio: χ2 = 1.676, P = .4325). It was suggested that decreased HMW adiponectin is a predictor of the progression to metabolic syndrome in a 6-year follow-up study of Japanese men. Furthermore, it was suggested longitudinally that measuring HMW adiponectin is efficient to predict the progression to metabolic syndrome compared with measuring total adiponectin or HMW-total adiponectin ratio.

Introduction

Adiponectin (also named Acrp30 [1], AdipoQ [2], GBP28 [3], and apM1 [4]) is an adipocyte-specific secretory protein that circulates in serum in at least 3 forms: low-molecular-weight, middle-molecular-weight, and high-molecular-weight (HMW) form multimer including 12mer and 18mer [5], [6], [7]. Serum adiponectin level is reported to correlate well with insulin sensitivity and lipid metabolism [8], [9]. There have been many reports that adiponectin is related to metabolic syndrome [10], [11], type 2 diabetes mellitus [12], [13], [14], obesity [15], and arteriosclerosis [16], [17]. Its level is reported to be decreased in patients and animal models of obesity, diabetes, and coronary artery disease (CAD) [15], [18], [19], [20]; and weight reduction increased the adiponectin level in obese patients [19]. Moreover, adiponectin is reported to have protective activities on the vasculature [16], [17], [21], [22], [23].

Recent studies have demonstrated that the HMW multimer form of adiponectin is the active form of this protein [6], [24], [25]: For example, it was reported that the HMW form of adiponectin stimulated the phosphorylation of 5′-adenosine monophosphate–activated protein kinase [6], [24]; the HMW form was the most active form in suppressing hepatic glucose production [6]; and Kobayashi et al [25] reported that only HMW adiponectin selectively suppressed endothelial cell apoptosis, whereas neither the low- nor the middle-molecular-weight form had this effect.

Clinical data also confirmed that type 2 diabetes mellitus patients with CAD have a selective reduction in HMW adiponectin [25], [26], [27]. Furthermore, weight reduction [25] preferentially increased the HMW form of adiponectin but not the other 2 oligomeric complexes. Waki et al [6] revealed that human adiponectin with rare missense mutations (G84R and G90S) did not form HMW multimers. These mutations were associated with insulin resistance and type 2 diabetes mellitus. They concluded that the proportion of each adiponectin oligomeric complex is important for the antidiabetic and antiatherogenic activities of this protein [6].

Several reports have shown that HMW adiponectin is more useful than total adiponectin. Especially in patients with type 2 diabetes mellitus receiving medication including thiazolidinediones, HMW-total adiponectin ratio was reported to be more useful than simply measuring serum total adiponectin level: for example, Pajvani et al [26] reported that HMW-total adiponectin ratio was significantly more useful to monitor the improvement of insulin sensitivity in response to thiazolidinediones in type 2 diabetes mellitus; Hara et al [11] reported that the HMW-total adiponectin ratio had better predictive power for the prediction of insulin resistance and metabolic syndrome than plasma total adiponectin level; and Aso et al [27] reported that HMW-total adiponectin ratio was more useful to evaluate CAD in type 2 diabetes mellitus patients than simply measuring serum total adiponectin. We have reported a cross-sectional study in healthy Japanese male subjects without any medication that showed that measuring HMW adiponectin was as effective as HMW-total adiponectin ratio to predict insulin resistance and/or metabolic syndrome [28].

Recently, longitudinal data concerning HMW adiponectin have been reported. For example, decreased HMW adiponectin was an independent risk factor for the progression to type 2 diabetes mellitus in Japanese Americans during a 5.4-year follow-up study [29]; and Inoue et al [30] reported that serum HMW adiponectin level was a predictor of future cardiovascular events in patients with CAD during 7 years of follow-up.

The aim of this study was to investigate longitudinally whether measuring serum HMW adiponectin might be useful to predict the progression to metabolic syndrome compared with total adiponectin or HMW-total ratio in nondiabetic Japanese subjects.

Section snippets

Subjects

This study included 416 Japanese male teachers and workers at Keio University, aged 30 to 59 years at baseline, who underwent annual health checkups in both 2000 and 2006. Subjects with metabolic syndrome, endocrine disease, or significant renal or hepatic disease, and those receiving medication for diabetes mellitus at baseline were excluded. Twenty-six subjects were receiving hydroxymethylglutaryl–coenzyme A inhibitor, but none was receiving niacin in this study. The present study was

Results

Of 416 men, 27 developed metabolic syndrome during the follow-up period of 6 years. Baseline characteristics of subjects who did and did not develop metabolic syndrome are shown in Table 1. At baseline, HMW adiponectin concentration was significantly lower in subjects who developed metabolic syndrome than in those who did not (P = .0143).

Baseline characteristics of subjects with HMW adiponectin concentration less than or equal to 2.65 μg/mL and those with HMW adiponectin concentration greater

Discussion

Recently, longitudinal studies showing the clinical usefulness of HMW adiponectin level in circulation have been reported: for example, it was reported that decreased HMW adiponectin was an independent risk factor for the progression to type 2 diabetes mellitus in Japanese Americans during a 5.4-year follow-up study [29]. Inoue et al [30] also reported that serum HMW adiponectin level may serve as a predictor of future cardiovascular events in patients with CAD.

The present longitudinal study

Acknowledgment

This study was supported in part by a Grant-in Aid from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (to HH), and by research grants (to HH) from Keio University, Tokyo.

References (33)

  • PajvaniU.B. et al.

    Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity

    J Biol Chem

    (2004)
  • SeinoY. et al.

    High molecular weight multimer form adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men

    Metabolism

    (2007)
  • InoueT. et al.

    High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease

    Am J Cardiol

    (2007)
  • NakanoY. et al.

    Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma

    J Biochem (Tokyo)

    (1996)
  • BergA.H. et al.

    The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

    Nat Med

    (2001)
  • YamauchiT. et al.

    The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

    Nat Med

    (2001)
  • Cited by (64)

    • Biomarkers in metabolic syndrome

      2022, Advances in Clinical Chemistry
    • Leptin/Adiponectin ratio as a potential biomarker for metabolic syndrome in patients with schizophrenia

      2018, Psychoneuroendocrinology
      Citation Excerpt :

      But the Multi-Ethnic Study of Atherosclerosis has demonstrated that there are consistent associations of leptin, adiponectin, and L/A ratio with insulin resistance across ethnic groups (Rasmussen-Torvik et al., 2012). Fourth, some potential inflammatory and metabolic markers of MetS, such as C-reactive protein (Mori et al., 2015), HbA1c (Hanssens et al., 2006), and high molecular weight adiponectin (Seino et al., 2009), were not measured. But the superiority of high molecular weight adiponectin over total adiponectin to distinguish subjects with MetS is still inconsistent (Chen et al., 2011a; Nakashima et al., 2011).

    • Adiponectin and Its Isoforms in Pathophysiology

      2018, Advances in Clinical Chemistry
    • What is the best biomarker for metabolic syndrome diagnosis?

      2015, Diabetes and Metabolic Syndrome: Clinical Research and Reviews
      Citation Excerpt :

      Adiponectin has been shown to increase insulin sensitivity and decrease plasma glucose by increasing tissue fat oxidation [19]. The HMW is the most active form in suppressing hepatic glucose production and only HMW selectively suppressed endothelial cell apoptosis, whereas neither the low nor the middle molecular weight form had this effect [20]. Our findings can report that leptin is higher in MetS group but adiponectin is lower (<4 μg/ml) and it shows the paradoxical effect of them in MetS.

    View all citing articles on Scopus

    Disclosure statement: Fujirebio, Tokyo, Japan (formerly Chugai Diagnostic Science, Tokyo), and Dr Hirose have a partial patent concerning HMW adiponectin measurement.

    View full text